Lexaria Bioscience Corp. (LEXX)
| Previous close | 3.1300 |
| Open | 3.4400 |
| Bid | 3.1200 x 300 |
| Ask | 3.3300 x 100 |
| Day's range | 3.2000 - 3.4400 |
| 52-week range | 0.6490 - 6.8500 |
| Volume | |
| Avg. volume | 509,030 |
| Market cap | 41.879M |
| Beta (5Y monthly) | 0.95 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6700 |
| Earnings date | 12 July 2024 - 16 July 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.00 |
Simply Wall St.This Lexaria Bioscience Insider Increased Their Holding By 23% Last Year
Insiders were net buyers of Lexaria Bioscience Corp.'s ( NASDAQ:LEXX ) stock during the past year. That is, insiders...
GlobeNewswireLexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
NEW YORK, Jan. 11, 2024 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/e7Vus With each new study, the horizon of GLP-1’s therapeutic potential expands, painting a vibrant picture of a future where a single molecu
- GlobeNewswire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Exciting New Cures Possible from GLP-1 Diabe
